2810022L02Rik Inhibitors
Chemical inhibitors of the protein 2810022L02Rik play a crucial role in modulating its function by disrupting various signaling pathways in which it is involved. Wortmannin and LY294002 are two such inhibitors that target the phosphoinositide 3-kinases (PI3K), a group pivotal to the PI3K/Akt pathway. Inhibition of PI3K consequently prevents the activation of downstream signaling necessary for the functional activity of 2810022L02Rik. Similarly, PD98059 and U0126 focus on inhibiting MEK1/2, which are upstream of extracellular signal-regulated kinases (ERK). By preventing MEK activation, these inhibitors indirectly prevent ERK activation, which is essential for the functional activity of 2810022L02Rik. Furthermore, SB203580 and SB202190 specifically target p38 MAP kinase, a critical component of the MAPK signaling pathway. By inhibiting p38 MAP kinase, these inhibitors disrupt the pathways that require p38 MAPK signaling, thus impeding the activity of 2810022L02Rik.
Other chemical inhibitors such as SP600125, Rapamycin, and PP2 work through different mechanisms but ultimately converge on the inhibition of 2810022L02Rik. SP600125 impedes the activity of JNK, which is part of the signaling pathways involving 2810022L02Rik. Rapamycin directly inhibits mTOR, a central regulator of cell growth and proliferation, affecting the pathways in which 2810022L02Rik is engaged. PP2 suppresses Src family kinases, which have upstream effects on the signaling involving 2810022L02Rik. Finally, inhibitors like GF109203X, Staurosporine, and Bisindolylmaleimide I target protein kinase C (PKC) and a broad spectrum of protein kinases, respectively. By inhibiting these kinases, they disrupt the signaling pathways crucial to 2810022L02Rik, consequently inhibiting its functional activity. Each inhibitor, through its unique target and mechanism, contributes to the modulation of the protein 2810022L02Rik's role in cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), and since 2810022L02Rik is involved in PI3K signaling pathways, inhibition of PI3K will inhibit the downstream signaling necessary for the full functional activity of 2810022L02Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, and by inhibiting this kinase, it would disrupt the PI3K/Akt pathway, which is crucial for many cellular processes that 2810022L02Rik may be involved in, leading to the inhibition of 2810022L02Rik's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK; since 2810022L02Rik is part of a pathway that involves ERK signaling, blocking MEK will prevent ERK activation, thereby inhibiting the functional activity of 2810022L02Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, and by preventing MEK activation, it inhibits the ERK pathway, which is necessary for the full functional activity of 2810022L02Rik; therefore, U0126 inhibits the functional activity of 2810022L02Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, and 2810022L02Rik is involved in pathways that require p38 MAPK signaling; inhibition of p38 MAPK would therefore inhibit the functional activity of 2810022L02Rik. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is an inhibitor of p38 MAP kinase as well, and by inhibiting p38, it would inhibit the signaling required for the function of 2810022L02Rik, leading to the inhibition of its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, and as JNK is part of the signaling pathways in which 2810022L02Rik operates, inhibition of JNK signaling can inhibit the functional activity of 2810022L02Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin directly inhibits mTOR, which is a central regulator of cell growth and proliferation, pathways that 2810022L02Rik is known to be involved in; thus, inhibition of mTOR would lead to the inhibition of 2810022L02Rik's function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits Src family kinases, which are upstream of various pathways involving 2810022L02Rik; by inhibiting Src kinases, PP2 would inhibit the functional activity of 2810022L02Rik. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is an inhibitor of protein kinase C, and since 2810022L02Rik is part of signaling pathways that involve PKC, inhibition of PKC can lead to the inhibition of 2810022L02Rik's function. | ||||||